Lucrezia Colonna1, Christian Lood, Keith B Elkon. 1. Division of Rheumatology, University of Washington, Seattle, Washington, USA *Lucrezia Colonna and Christian Lood contributed equally to the writing of this article.
Abstract
PURPOSE OF REVIEW: Systemic lupus erythematosus (SLE) is characterized by autoantibodies directed against nuclear autoantigens normally concealed from immune recognition in healthy individuals. Here, we summarize recently identified mechanisms of abnormal cell death leading to exposure and aberrant processing of nucleoprotein self antigens, and discuss their role in the SLE pathogenesis. RECENT FINDINGS: During the past few years, the unveiling of several new forms of cell death has expanded our understanding beyond the simple view of 'apoptotic' versus 'necrotic' cell death. SLE patients show abnormalities in cell death at several levels, including increased rates of apoptosis, necrosis, and autophagy, as well as reduced clearance of dying cells. These abnormalities lead to an increased autoantigen burden and antigen modifications, such as nucleic acid oxidation that increases the inflammatory properties of self antigens. Recent investigations have highlighted the role of opsonins in determining the immunogenic versus tolerogenic characteristics of self antigens. SUMMARY: Dysregulation of different forms of programmed cell death contributes to increased exposure, availability, and immunogenic characteristics of intracellular self antigens, which all participate in development of lupus autoimmunity. As our understanding of abnormalities of cell death in SLE advances, potential therapeutic opportunities await human implementation.
PURPOSE OF REVIEW: Systemic lupus erythematosus (SLE) is characterized by autoantibodies directed against nuclear autoantigens normally concealed from immune recognition in healthy individuals. Here, we summarize recently identified mechanisms of abnormal cell death leading to exposure and aberrant processing of nucleoprotein self antigens, and discuss their role in the SLE pathogenesis. RECENT FINDINGS: During the past few years, the unveiling of several new forms of cell death has expanded our understanding beyond the simple view of 'apoptotic' versus 'necrotic' cell death. SLEpatients show abnormalities in cell death at several levels, including increased rates of apoptosis, necrosis, and autophagy, as well as reduced clearance of dying cells. These abnormalities lead to an increased autoantigen burden and antigen modifications, such as nucleic acid oxidation that increases the inflammatory properties of self antigens. Recent investigations have highlighted the role of opsonins in determining the immunogenic versus tolerogenic characteristics of self antigens. SUMMARY: Dysregulation of different forms of programmed cell death contributes to increased exposure, availability, and immunogenic characteristics of intracellular self antigens, which all participate in development of lupus autoimmunity. As our understanding of abnormalities of cell death in SLE advances, potential therapeutic opportunities await human implementation.
Authors: James M Murphy; Peter E Czabotar; Joanne M Hildebrand; Isabelle S Lucet; Jian-Guo Zhang; Silvia Alvarez-Diaz; Rowena Lewis; Najoua Lalaoui; Donald Metcalf; Andrew I Webb; Samuel N Young; Leila N Varghese; Gillian M Tannahill; Esme C Hatchell; Ian J Majewski; Toru Okamoto; Renwick C J Dobson; Douglas J Hilton; Jeffrey J Babon; Nicos A Nicola; Andreas Strasser; John Silke; Warren S Alexander Journal: Immunity Date: 2013-09-05 Impact factor: 31.745
Authors: K Lauber; H Keppeler; L E Munoz; U Koppe; K Schröder; H Yamaguchi; G Krönke; S Uderhardt; S Wesselborg; C Belka; S Nagata; M Herrmann Journal: Cell Death Differ Date: 2013-07-05 Impact factor: 15.828
Authors: Roshan J Thapa; Shoko Nogusa; Peirong Chen; Jenny L Maki; Anthony Lerro; Mark Andrake; Glenn F Rall; Alexei Degterev; Siddharth Balachandran Journal: Proc Natl Acad Sci U S A Date: 2013-07-29 Impact factor: 11.205
Authors: Zaida G Ramirez-Ortiz; William F Pendergraft; Amit Prasad; Michael H Byrne; Tal Iram; Christopher J Blanchette; Andrew D Luster; Nir Hacohen; Joseph El Khoury; Terry K Means Journal: Nat Immunol Date: 2013-07-28 Impact factor: 25.606
Authors: Elisabet Svenungsson; Daniel Engelbertsen; Maria Wigren; Johanna T Gustafsson; Iva Gunnarsson; Kerstin Elvin; Kerstin Jensen-Urstad; Gunilla Nordin Fredrikson; Jan Nilsson Journal: Clin Exp Immunol Date: 2015-06-22 Impact factor: 4.330
Authors: Sladjana Skopelja-Gardner; Lucrezia Colonna; Payton Hermanson; Xizhang Sun; Lena Tanaka; Joyce Tai; Yenly Nguyen; Jessica M Snyder; Charles E Alpers; Kelly L Hudkins; David J Salant; YuFeng Peng; Keith B Elkon Journal: J Immunol Date: 2020-04-01 Impact factor: 5.422